What really matters isn't the company's numbers last night but
how the company eventually monetizes their vast IP in the future.
Biotech/Therapeutic companies real value lies in their
pipeline. This is a speculative biotech company and one
should avoid unless comfortable with such risk and
volatility.
As far as numbers, quite impressive for a biotech/therapeutic
company to be positive cash flow at such an early stage but this
can change and stock has higher market cap. With that being
said, the real value in the company is found in their proprietary
databank (largest collection of genetic disease markers in the
world) and the diagnostics and therapeutics that are developed from
that database. Below is a link showing the
background on some of their team and quick synopsis of the
first market the company will enter based upon their proprietary
data. Other thing to watch for is partnerships - especially
Asia. The question is how and when this can be monetized in
the future...remains a spec play only at this stage after booking
profits on big move earlier this year.
Do your own due diligence and stick to your plan - remain
disciplined on trades as this company is still in the early stages
(speculative). Keep stops in place and view as trade now
only.
Newsletter
Subscribe to our email list for regular free market updates
as well as a chance to get coupons!
PRED Steve, what did you think
Posted by soldado1976 on 1st of Oct 2019 at 08:18 am
PRED
Steve, what did you think of the PRED numbers released last night?
What really matters isn't the
Posted by steve on 1st of Oct 2019 at 08:41 am
What really matters isn't the company's numbers last night but how the company eventually monetizes their vast IP in the future. Biotech/Therapeutic companies real value lies in their pipeline. This is a speculative biotech company and one should avoid unless comfortable with such risk and volatility.
As far as numbers, quite impressive for a biotech/therapeutic company to be positive cash flow at such an early stage but this can change and stock has higher market cap. With that being said, the real value in the company is found in their proprietary databank (largest collection of genetic disease markers in the world) and the diagnostics and therapeutics that are developed from that database. Below is a link showing the background on some of their team and quick synopsis of the first market the company will enter based upon their proprietary data. Other thing to watch for is partnerships - especially Asia. The question is how and when this can be monetized in the future...remains a spec play only at this stage after booking profits on big move earlier this year.
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=151282922
Do your own due diligence and stick to your plan - remain disciplined on trades as this company is still in the early stages (speculative). Keep stops in place and view as trade now only.